NCT06073873View on ClinicalTrials.gov

A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
Ulcerative Colitis
Interventions
DRUG

Ozanimod

According to local product label

Trial Locations (1)

06178

RECRUITING

Bristol-Myers Squibb YH, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06073873 - A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea | Biotech Hunter | Biotech Hunter